EUVIMEDEUVIMED entdecken
Übersichtsarbeit

First-line systemic therapy for advanced or metastatic esophageal squamous cell carcinoma: clinical implications for treatment selection after KEYNOTE-590, CheckMate 648, and RATIONALE-306

Tamotsu Sagawa, Hiroyuki Nagashima, Koshi Fujikawa

Clinical Journal of Gastroenterology · 2026

DOI: 10.1007/s12328-026-02447-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Journal of Gastroenterology, 2026. Verfasst von Tamotsu Sagawa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-jo 2-chome, Shiroishi-ku, Sapporo-shi, Hokkaido…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Esophageal Squamous Cell Carcinoma, Immune Checkpoint Inhibitors. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

First-line systemic therapy for unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) has been reshaped by PD-1 blockade, but treatment selection remains complex because the pivotal trials differ in chemotherapy backbone and PD-L1 scoring methodology. KEYNOTE-590 enrolled both ESCC and adenocarcinoma and established pembrolizumab plus chemotherapy as a durable chemoimmunotherapy standard across histologic subtypes. CheckMate 648, focused on ESCC, showed that nivolumab plus chemotherapy and nivolumab plus ipilimumab both improve overall survival (OS), although the patterns of benefit are distinct: progression-free survival (PFS) benefit was observed with nivolumab plus chemotherapy but not with nivolumab plus ipilimumab. RATIONALE-306 subsequently added tislelizumab plus chemotherapy as another evidence-based first-line option in ESCC. Accordingly, clinically relevant treatment selection is better framed by the need for rapid disease control, tolerance for chemotherapy, toxicity profile, histology, and biomarker context than by a simple comparison of individual antibodies. Interpretation of PD-L1 also requires caution because KEYNOTE-590 used combined positive score (CPS), CheckMate 648 used tumor-cell PD-L1 expression, and RATIONALE-306 used Tumor Area Positivity (TAP). This review summarizes the evidence supporting current first-line treatment selection and its implications for daily clinical practice. Key issues addressed include practical distinctions between chemoimmunotherapy and dual immune checkpoint blockade, harmonization of PD-L1 assessment, platinum-backbone selection, and the optimization of treatment sequencing after first-line immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsEsophageal Squamous Cell CarcinomaImmune Checkpoint InhibitorsHumansAntibodies, Monoclonal, HumanizedNivolumabIpilimumabB7-H1 Antigen

Stichwörter der Autor:innen

ChemoimmunotherapyEsophageal squamous cell carcinomaFirst-line therapyPD-1 inhibitorPD-L1

Substanzen

Antibodies, Monoclonal, HumanizedNivolumabpembrolizumabtislelizumabIpilimumabB7-H1 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-jo 2-chome, Shiroishi-ku, Sapporo-shi, Hokkaido, 003-0804, Japan. stamotsu@jk9.so-net.ne.jp.
  • Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 3-54 Kikusui 4-jo 2-chome, Shiroishi-ku, Sapporo-shi, Hokkaido, 003-0804, Japan.

Zitieren

APA

Sagawa, T., Nagashima, H., & Fujikawa, K. (2026). First-line systemic therapy for advanced or metastatic esophageal squamous cell carcinoma: clinical implications for treatment selection after KEYNOTE-590, CheckMate 648, and RATIONALE-306. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-026-02447-5

Vancouver

Sagawa T, Nagashima H, Fujikawa K. First-line systemic therapy for advanced or metastatic esophageal squamous cell carcinoma: clinical implications for treatment selection after KEYNOTE-590, CheckMate 648, and RATIONALE-306. Clinical Journal of Gastroenterology. 2026. doi:10.1007/s12328-026-02447-5

BibTeX
@article{Sagawa2026,
  author = {Sagawa, Tamotsu and Nagashima, Hiroyuki and Fujikawa, Koshi},
  title = {First-line systemic therapy for advanced or metastatic esophageal squamous cell carcinoma: clinical implications for treatment selection after KEYNOTE-590, CheckMate 648, and RATIONALE-306},
  journal = {Clinical Journal of Gastroenterology},
  year = {2026},
  doi = {10.1007/s12328-026-02447-5}
}
Kostenlos starten →